secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001193125-22-212597
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Q2 2022 revenue $73.7M, net loss $9.9M; cash $688.6M; pipeline data positive
--------------------------------------------------------------------------------

- Net loss attributable to common stockholders of $9.9M ($0.07 per share) vs $96.3M loss a year ago; revenue $73.7M from NULIBRY and licensing.
- Cash and equivalents $688.6M, providing runway into 2024; two-year deferral on senior debt principal repayment to Nov 2026.
- Positive Phase 2 interim data for infigratinib in achondroplasia: mean AHV increase 1.52 cm/year; added Cohort 5.
- Entered exclusive license with BMS for BBP-398 (SHP2 inhibitor) for up to $905M; received $90M upfront; sold PRV for $110M.
- Selected next-gen KRAS G12C dual inhibitor candidate; plans to begin clinical work mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000119312522212597/0001193125-22-212597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000119312522212597/d365371d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-212597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer